The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
The mGluR5 antagonist MPEP decreases operant ethanol self-administration during maintenance and after repeated alcohol deprivations in alcohol-preferring (P) rats
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug Addiction, Dysregulation of Reward, and Allostasis
Koob, G. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00195-0 · Cited by 2,953
Naltrexone in the Treatment of Alcohol Dependence
Krystal, J. H., Cramer, J. A., Krol, W. F., Kirk, G. F., & Rosenheck, R. A. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011127 · Cited by 618
Gereau, R., & Conn, P. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-10-06879.1995 · Cited by 352
Cited by
Neuropharmacology of alcohol addiction
Vengeliene, V, Bilbao, A., Molander, A., & Spanagel, R. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.30 · Cited by 571
Glutamatergic substrates of drug addiction and alcoholism
Gass, J. T., & Olive, M. F. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.06.039 · Cited by 484
Pharmacological treatment of alcohol dependence: Target symptoms and target mechanisms
HEILIG, M., & EGLI, M. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.02.001 · Cited by 377
Glutamatergic targets for new alcohol medications
Holmes, A., Spanagel, R., & Krystal, J. H. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3226-2 · Cited by 197
“In addition, multiple studies have now shown that the mGluR5 deletion or antagonist treatment with MPEP and MTEP attenuates alcohol drinking, withdrawal, place preference and cue-induced alcohol-seeking (Adams et al. 2008; Backstrom et al. 2004; Backstrom and Hyytia 2006; 2007; Besheer et al. 2008; Besheer et al. 2010…”
Coller, J. K., & Hutchinson, M. R. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.01.008 · Cited by 186
Targeting glutamate uptake to treat alcohol use disorders
Rao, P. S. S., Bell, R. L., Engleman, E. A., & Sari, Y. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00144 · Cited by 136
“Similarly, antagonists of mGluR5 are also found to be beneficial in preventing alcohol relapse in a genetic animal model of alcoholism (Schroeder et al., 2005).”
BackgroundBlednov, Y. A., & Adron Harris, R. (2008) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145708008584 · Cited by 123
Role of glutamatergic system and mesocorticolimbic circuits in alcohol dependence
Alasmari, F., Goodwani, S., McCullumsmith, R. E., & Sari, Y. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.10.001 · Cited by 85
Bell, R. L., Hauser, S. R., McClintick, J., Rahman, S., Edenberg, H. J., Szumlinski, K. K., & McBride, W. J. (2016) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2015.10.018 · Cited by 65
“However, systemic JNJ 16259685 pretreatment has nonselective effects in that it also reduces locomotor activity,(135,143) which may reflect the high abundance of mGlu1 receptors in the cerebellum and their effects on its control of motor movement.(134,135,143)”
Caprioli, D., Justinova, Z., Venniro, M., & Shaham, Y. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.08.018 · Cited by 55
Hwa, L., Besheer, J., & Kash, T. (2017) · F1000Research · doi:10.12688/f1000research.9609.1 · Cited by 39
Yohn, S. E., Galbraith, J., Calipari, E. S., & Conn, P. J. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00601 · Cited by 36
The metabotropic glutamate receptor 5 as a biomarker for psychiatric disorders
(2023) · International Review of Neurobiology · doi:10.1016/bs.irn.2022.10.007 · Cited by 8
Metadata
- Authors
- Schroeder, J. P., Overstreet, D. H., & Hodge, C. W.
- Venue
- Psychopharmacology
- Published
- 2005-02-17
- Volume
- 179
- Issue
- 1
- Pages
- 262-270
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2005019035
- Cited by
- 161
- References
- 3
- FWCI
- 4.87
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.